相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative effectiveness of dapagliflozin vsDPP-4 inhibitors on a composite endpoint ofHbA1c, body weight and blood pressure reduction in the real world
Mario Luca Morieri et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2021)
Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide (Ideglira)
Luciano Zenari et al.
DIABETES THERAPY (2021)
Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life
Stefano Rizza et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care
Benedetta Maria Bonora et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
Gian Paolo Fadini et al.
DIABETES THERAPY (2021)
Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
Cheli Melzer-Cohen et al.
DIABETES THERAPY (2020)
Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice
Leonard E. Egede et al.
DIABETES THERAPY (2020)
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
Tina Vilsboll et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies
Gian Paolo Fadini et al.
DIABETES OBESITY & METABOLISM (2019)
GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use-A DEVOTE Subanalysis
Kirstine Brown-Frandsen et al.
DIABETES (2018)
Liraglutide Effects in Insulin-Treated Patients in LEADER
Cornelis Tack et al.
DIABETES (2018)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
Hermione Price et al.
DIABETES OBESITY & METABOLISM (2018)
Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
Maria Ida Maiorino et al.
DIABETES OBESITY & METABOLISM (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Physicians' real-world experience with IDegLira: results of a European survey
Russell Drummond et al.
BMJ OPEN DIABETES RESEARCH & CARE (2018)
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al.
DIABETES OBESITY & METABOLISM (2017)
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial
H. W. Rodbard et al.
DIABETIC MEDICINE (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
Stewart B. Harris et al.
DIABETES OBESITY & METABOLISM (2017)
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists
Francesco Giorgino et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes The DUAL V Randomized Clinical Trial
Ildiko Lingvay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
John B. Buse et al.
DIABETES CARE (2014)
分享论文
